Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL29969023

NS(=O)(=O)c1cccnc1.O=C(O)C(F)(F)F

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.51
CA2 P00918 5/20 0.49
CA12 O43570 4/20 0.49
CA1 P00915 4/20 0.49
CA9 Q16790 4/20 0.49
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
PTGS2 P35354 3/20 0.43
ABCC9 O60706 1/20 0.43
ABCC8 Q09428 1/20 0.43
KCNJ11 Q14654 1/20 0.43
KCNJ8 Q15842 1/20 0.43
ATR Q13535 1/20 0.43
KDM4E B2RXH2 2/20 0.43
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pivalate SCHEMBL17498118 0.87 NAPRT (0.51) NAPRTCA2CA12CA1CA9
SCHEMBL393736 0.84 CA2 (0.63) NAPRTCA2CA12CA1CA9
SCHEMBL29614165 0.84 CA2 (0.63) NAPRTCA2CA12CA1CA9
Hydrochloric Acid SCHEMBL28262884 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
Hydrochloric Acid SCHEMBL1774480 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
SCHEMBL17476040 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
Fluoride SCHEMBL28328135 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
Hydrochloric Acid SCHEMBL29968745 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
Potassium SCHEMBL17476041 0.82 CA2 (0.61) NAPRTCA2CA12CA1CA9
Fumaric Acid SCHEMBL27601601 0.82 NAPRT (0.53) NAPRTCA2CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187742-B2 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy XRAD THERAPEUTICS, INC. (US) 2025-01-07 US disclosed
CN-112638898-B Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors 泽农医药公司 2024-04-09 CN disclosed
US-20220315606-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY XRAD HOLDING CAYMAN LIMITED (KY) 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315606-A1 DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY ATM, CHEK2, CHEK1 NAPRT 3015/4885CA2 4355/4885CA12 4635/4885
US-12187742-B2 Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy ATM, CHEK2, CHEK1 NAPRT 3015/4885CA2 4355/4885CA12 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.